Navigation Links
Researchers use light to measure cancer cells' response to treatment
Date:12/20/2011

WASHINGTON, Dec. 20Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively. The team has demonstrated a new way to optically test cultured cancer cells' response to a particular cancer drug. The results appear in the December issue of the Optical Society's (OSA (http://www.osa.org)) open-access journal Biomedical Optics Express (http://www.opticsinfobase.org/boe).

Certain cancer cells display a higher-than-normal number of proteins called human epidermal growth factor receptor 2 (HER2). In healthy cells, HER2 helps mediate cell growth, but overexpression of HER2 can mark one of the most aggressive forms of breast cancer. Drugs that bind to and block growth factor receptors have been shown to prolong life in some cancer patients, but about 30 percent of HER2 overexpressing tumors do not respond to the drug. Tests to identify these non-responding tumors early on would help doctors make important treatment decisions that could improve patient outcomes.

To design such a test, the Vanderbilt team took advantage of the fact that some cancer cells preferentially use a different metabolic pathway when compared to normal cells. The researchers visualized the relative use of the different pathways by shining the cells with frequencies of light that caused two different metabolic molecules to naturally fluoresce. They then calculated a ratio between the two levels of fluorescence, called an optical redox ratio. The team found that, of the different cell lines they tested, HER2 overexpressing cells had the highest optical redox ratio. They also found that when HER2 cancer cells were treated with an HER2-blocking drug, the ratio decreased. This decrease, however, was not observed in cancer cells that were resistant to the drug. The findings lay the groundwork for future in vivo studies and hold the promise that real-time tumor response to treatment might be measured optically.


'/>"/>
Contact: Angela Stark
astark@osa.org
202-416-1443
Optical Society of America
Source:Eurekalert

Related medicine news :

1. MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain
2. MU researchers find pet kidney injuries are similar to human kidney injuries
3. UC Irvine researchers urge caution when buying noisy toys
4. Ohio State researchers discover hereditary predisposition of melanoma of the eye
5. Researchers investigate link between autoimmune diseases and wounds that dont heal
6. Researchers describe a new genetic program that converts static cells into mobile invasive cells
7. UIC researchers discover how cells limit inflammation in lung injury
8. Researchers identify phthalates in numeruous medicines and supplements
9. BUSM researchers find link between pulmonary inflammation, diesel exhaust, house dust
10. Jefferson researchers mirror human response to bacterial infection and resolution in mice
11. Leibniz Prize 2012 to honor 11 outstanding researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: